HDL in Morbidity and Mortality: A 40+ Year Perspective
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The first large population-based study to show an inverse relationship between circulating HDL-cholesterol (HDL-C) concentrations and coronary heart disease (CHD) was a cross-sectional analysis of men of Japanese ancestry living in Hawaii (1,). Four prospective epidemiological studies extended these finding showing that a 1 mg/dL increase in HDL-C was associated with a 2% decrease in CHD in men and a 3% decrease in CHD in women (2). The inverse relationship was independent of age, smoking, low density lipoprotein cholesterol (LDL-C), blood pressure, and body mass index (BMI), but was attenuated by adjustment for non-HDL-C (i.e., VLDL+LDL-C) concentrations. These findings suggested that raising HDL-C could be therapeutically beneficial but were insufficient to completely disentangle the close relationship between HDL and triglyceride-rich lipoproteins. The subsequent failure of most clinical trials aimed at raising HDL-C concentrations, especially the trials conducted with cholesteryl ester transfer protein (CETP) inhibitors, as well as detailed studies of the genetic factors underlying HDL-C variation have called into question the causal relationship between HDL-C and CHD, and have refuted the idea that raising HDL-C would automatically have therapeutic benefit. Nonetheless, HDL-C remains an important CHD risk factor that appears in American Heart Association and European Atherosclerosis Society guidelines to estimate risk and guide treatment. HDL-C measurements may integrate the effects of multiple risk factors including obesity, insulin resistance and hypertension. Moreover, an abundance of evidence indicates that the ability of HDL to mediate cholesterol efflux from macrophage foam cells does associate with protection from atherosclerosis, holding promise for future therapies targeting this mechanism. This brief review will provide a personal perspective on HDL research that has benefited from the contributions of many different laboratories (Table 1). Milestones in HDL science. Epidemiological studies reveal an independent inverse relationship between HDL-C concentrations and CHD (1976) Elucidation of monogenic disorders affecting HDL-C concentrations including CETP deficiency (1989) CETP inhibitors developed as potential antiatherogenic therapies (1990) APOA1 overexpression reduces atherosclerosis in animal models (1991) ABCA1 deficiency elucidated as the cause of Tangier Disease (1999) ABCA1 found to be an LXR target (2000) LXR activators reduce atherosclerosis (2002) The first CETP inhibitor in clinical trials (torcetrapib) increases CHD and overall mortality (2007) Dozens of novel SNPs found to associate with HDL concentrations in human GWAS (2010) Cholesterol efflux capacity of HDL correlates inversely with CHD independent of HDL-C (2011) Mendelian Randomization studies suggest that SNPs that associate with HDL-C concentrations do not associate with CHD (2012) The CETP inhibitor anacetrapib produces a significant but moderate reduction in CHD. The sponsors decline to seek marketing approval (2017) Reconstituted HDL preparations optimized for human phase 3 studies (2018) Epidemiological studies reveal an independent inverse relationship between HDL-C concentrations and CHD (1976) Elucidation of monogenic disorders affecting HDL-C concentrations including CETP deficiency (1989) CETP inhibitors developed as potential antiatherogenic therapies (1990) APOA1 overexpression reduces atherosclerosis in animal models (1991) ABCA1 deficiency elucidated as the cause of Tangier Disease (1999) ABCA1 found to be an LXR target (2000) LXR activators reduce atherosclerosis (2002) The first CETP inhibitor in clinical trials (torcetrapib) increases CHD and overall mortality (2007) Dozens of novel SNPs found to associate with HDL concentrations in human GWAS (2010) Cholesterol efflux capacity of HDL correlates inversely with CHD independent of HDL-C (2011) Mendelian Randomization studies suggest that SNPs that associate with HDL-C concentrations do not associate with CHD (2012) The CETP inhibitor anacetrapib produces a significant but moderate reduction in CHD. The sponsors decline to seek marketing approval (2017) Reconstituted HDL preparations optimized for human phase 3 studies (2018) Milestones in HDL science. Epidemiological studies reveal an independent inverse relationship between HDL-C concentrations and CHD (1976) Elucidation of monogenic disorders affecting HDL-C concentrations including CETP deficiency (1989) CETP inhibitors developed as potential antiatherogenic therapies (1990) APOA1 overexpression reduces atherosclerosis in animal models (1991) ABCA1 deficiency elucidated as the cause of Tangier Disease (1999) ABCA1 found to be an LXR target (2000) LXR activators reduce atherosclerosis (2002) The first CETP inhibitor in clinical trials (torcetrapib) increases CHD and overall mortality (2007) Dozens of novel SNPs found to associate with HDL concentrations in human GWAS (2010) Cholesterol efflux capacity of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Cholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
Self-citationEffects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Common variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862 · cited 1×
“modeled the impact on CHD of 185 variants associated with LDL-C, HDL-C, or triglyceride (TG), and found that LDL-C and TG, but not HDL-C, are causally associated with CHD risk (10).”
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis
Westerterp, M., Fotakis, P., Ouimet, M., Bochem, A. E., Zhang, H., Molusky, M. M., Wang, W., Abramowicz, S., la Bastide-van Gemert, S., Wang, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032636 · Cited by 331
Self-citationAssociation of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
White, J., Swerdlow, D. I., Preiss, D., Fairhurst-Hunter, Z., Keating, B. J., Asselbergs, F. W., Sattar, N., Humphries, S. E., Hingorani, A. D., & Holmes, M. V. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1884 · Cited by 293 · cited 1×
“Multivariate MR of lipid traits in CHD using larger CHD datasets also detected an HDL-C association, but this association became nonsignificant after mathematical modeling of unmeasured pleiotropy; the TG relationship was also attenuated but remained significant (12).”
BackgroundWesterterp, M., Tsuchiya, K., Tattersall, I. W., Fotakis, P., Bochem, A. E., Molusky, M. M., Ntonga, V., Abramowicz, S., Parks, J. S., Welch, C. L., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306670 · Cited by 114
Self-citationTTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis
Hsieh, J., Koseki, M., Molusky, M. M., Yakushiji, E., Ichi, I., Westerterp, M., Iqbal, J., Chan, R. B., Abramowicz, S., Tascau, L., et al. (2016) · Nature · doi:10.1038/nature18628 · Cited by 106
Self-citationRader, D. J. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2168 · Cited by 32 · cited 1×
“The challenge has been to infuse sufficient amounts of reconstituted HDL of appropriate composition to stimulate cholesterol efflux without inducing hemolysis or hepato-toxicity (19).”
Background
Cited by
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Self-citation(2022) · doi:10.1101/2022.04.06.487425 · Cited by 4
Chew, B. L. A., Ngoh, A. Q., Phoo, W. W., Chan, K. W. K., Ser, Z., Tulsian, N. K., Lim, S. S., Weng, M. J. G., Watanabe, S., Choy, M. M., et al. (2024) · doi:10.7554/elife.90762.2
Metadata
- Authors
- Tall, A. R.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-11-22
- Volume
- 67
- Issue
- 1
- Pages
- 19-23
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W3108624167
- Cited by
- 26
- References
- 9
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.